IP Library Granted Patent US 9,272,006
Granted Patent B2
US 9,272,006 · App. 14/131,279 · Granted Mar 1, 2016

Process for detergent-free production of outer membrane vesicles of a gram-negative bacterium

Inventors: Bas Van De Waterbeemd (Utrecht, NL); Leonardus Aldolfus Van Der Pol (Groningen, NL)
Assignee: DE STAAT DER NEDERLANDEN, VERT. DOOR DE MINISTER VAN VWS MINISTERIE VAN VOLKSGEZONDHEID, WELZIJN EN SPORT
A61K35/74A61K39/095A61K2039/55505A61K2039/70
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,272,006
App. No.
14/131,279
Granted
Mar 1, 2016
Kind
B2
Abstract

The present invention relates to the fields of medical microbiology and vaccines. In particular the invention relates to a process for detergent-free preparation of outer membrane vesicles (OMV) of Gram negative bacteria for use in vaccines, to OMV obtainable by said process, and to a pharmaceutical composition comprising such OMV. The present invention further relates to the use of OMV of the present invention as a medicament in particular for use in a method for eliciting an immune response.

Claims (29)

1. A process for producing a detergent-free preparation of bacterial outer membrane vesicles (OMV) for use in vaccines, said process comprising the steps of:

(a) cultivating a population of Gram-negative bacteria in culture to stationary growth phase;

(b) beginning at a time at least about 1 hour after onset of the stationary growth phase, incubating the bacteria obtained in step (a) in a medium adjusted to, or having a pH higher than, pH 8.0 and a concentration of a metal chelating agent of between about 1 and 100 mM to extract said bacterial OMV; and

(c) after step (b), recovering the extracted bacterial OMV by separation of the bacterial OMV from the bacteria.

2. The process according to claim 1 , wherein the Gram-negative bacteria comprise a genetic modification which causes the bacteria to produce a lipopolysaccharide (LPS) with reduced toxicity compared to a corresponding wild-type LPS while retaining at least part of the LPS adjuvant activity, which genetic modification:

(i) decreases or knocks-out expression of one or more of the following genes:

(A) lpxL1 or a gene the sequence of which is at least 95% identical with SEQ ID NO:1;

(B) lpxL2; and

(C) lpxK;

and/or

(ii) effects expression of one or more of genes lpxE and/or pagL.

3. The process according to claim 1 , wherein the time after onset of the stationary growth phase during which the bacteria are incubated in the medium in step (b) is between about 1 and 9 hours.

4. The process according to claim 1 , further comprising a step of sterilizing the bacterial OMV.

5. The process according to claim 1 , wherein the concentration of the metal chelating agent in step (b) is between about 5 mM and 15 mM, and/or wherein the pH is between:

(i) pH 8.0 and pH 9.5, or

(ii) pH 8.0 and pH 9.0, or

(iii) pH 8.2 and pH 8.8, or

(iv) pH 8.4 and pH 8.7.

6. The process according to claim 1 , wherein the cultivating of step (a) and/or the incubating of step (b) is performed in a medium volume of at least about 10 liters.

7. The process according to claim 1 , wherein the Gram-negative bacteria are a species of the genera Neisseria or Bordetella.

8. The process according to claim 1 wherein the Gram-negative bacteria comprise one or more mutations that decrease or knock-out expression of a gene product.

9. The process according to claim 1 , wherein the Gram-negative bacteria are of multiple PorA subtypes.

10. The process according to claim 1 , wherein the bacterial population comprises Gram-negative bacteria of more than one strain wherein bacteria of each strain are of different PorA subtypes.

11. The process according to claim 1 , wherein the Gram-negative bacteria express an antigen that is foreign to the strain or species of said bacteria.

12. The process according to claim 1 , further comprising a step of combining the recovered bacterial OMV with a pharmaceutically acceptable excipient.

13. The process according to claim 1 wherein the chelating agent is EDTA.

14. The process according to claim 3 wherein the time after onset of the stationary growth phase during which the bacteria are incubated in the medium in step (b) is between about 2 and 5 hours.

15. The process according to claim 7 wherein the bacterial species is Neisseria meningitidis or Bordetella pertussis.

16. The process according to claim 8 wherein the gene product whose expression is decreased or knocked out is Cps or a product active in lipid A biosynthesis selected from the group consisting of LpxL1, RmpM, PorA, PorB and OpA.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 23, 2021
From: DE STAAT DER NEDERLANDEN, VERT. DOOR DE MINISTER VAN VWS, MINISTERIE VAN VOLKSGEZONDHEID, WELZIJN EN SPORT
To: INTRAVACC B.V.
Reel/Frame 057569/0636 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 18, 2015
From: VAN DE WATERBEEMD, BAS; VAN DER POL, LEONARDUS ALDOLFUS
To: DE STAAT DER NEDERLANDEN, VERT. DOOR DE MINISTER VAN VWS
Reel/Frame 037073/0197 →
Priority Claims (1)
EP 11173085 · Jul 7, 2011 · regional
Continuity (2)
Provisional Application 61505221 · Jul 7, 2011
Related Publication 20140147469A1 · May 29, 2014